Intratumoral Microdosing of TAK-981 in Head and Neck Cancer
Status:
Recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, single arm, open-label, multi-agent, localized pharmacodynamic
biomarker Phase 0 trial designed to study the biological effects within the tumor
microenvironment of TAK-981 and TAK-981 combined with cetuximab or avelumab when administered
intratumorally in microdose quantities via the CIVO device. CIVO stands for comparative in
vivo oncology.